$EQ

Tom Penny sold $192K of EQ

Tom Penny (Principal Accounting Officer) sold 65,000 shares of Equillium, Inc. (EQ) at $2.95 ($0.19M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tom Penny
Published May 29, 2026, 10:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EQ
Neutral
medium confidence
Mentioned
$EQ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQNeutralLow
01

Why it matters

The disclosed sale can influence short-term sentiment, but 10b5-1 pre-arrangement typically lowers interpretive value versus unscheduled selling.

02

Market read

Traders may monitor EQ for follow-on insider activity, but this specific filing alone is unlikely to drive a major repricing.

03

What to watch

The filing does not reveal remaining insider intent or whether other insiders/funds changed positions around the same time.

Relevance 6/10Novelty 6/10Timing: After-hours/filing timestamp (filed 2026-05-29) for a sale executed 2026-05-28

Background

The article is an SEC Form 4 insider transaction disclosure for Equillium, Inc. (EQ).

Company-level read

Ticker impact

$EQNeutralMedium confidence
Context

Equillium officer Tom Penny sold 65,000 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited immediate price impact; any reaction should be modest and short-lived unless accompanied by other catalysts.

Evidence & confidence

Form 4 shows an officer sale under a pre-arranged 10b5-1 plan and the article provides no accompanying fundamental change (earnings, trial, deal, or guidance).

Market effects

Minimal; this is company-specific insider transaction with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine diversification rather than a bearish view.

Key entities

  • Equillium, Inc.

    Company whose officer sale is disclosed via SEC Form 4.

  • Tom Penny

    Principal Accounting Officer who sold shares.

Related articles

$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP